Abstract
Polycystic ovary syndrome (PCOS) is a common disease of endocrine–metabolic disorder, and its etiology remains largely unknown. The gut microbiota is possibly involved in PCOS, while the association remains unclear. The comprehensive analysis combining gut microbiota with PCOS typical symptoms was performed to analyze the role of gut microbiota in PCOS in this study. The clinical patients and letrozole-induced animal models were determined on PCOS indexes and gut microbiota, and fecal microbiota transplantation (FMT) was conducted. Results indicated that the animal models displayed typical PCOS symptoms, including disordered estrous cycles, elevated testosterone levels, and ovarian morphological change; meanwhile, the symptoms were improved after FMT. Furthermore, the microbial diversity exhibited disordered, and the abundance of the genus Ruminococcus and Lactobacillus showed a consistent trend in PCOS rats and patients. The microbiota diversity and several key genera were restored subjected to FMT, and correlation analysis also supported relevant conclusions. Moreover, LEfSe analysis showed that Gemmiger, Flexispira, and Eubacterium were overrepresented in PCOS groups. Overall, the results indicate the involvement of gut microbiota in PCOS and its possible alleviation of endocrinal and reproductive dysfunctions through several special bacteria taxa, which can function as the biomarker or potential target for diagnosis and treatment. These results can provide the new insights for treatment and prevention strategies of PCOS.
Similar content being viewed by others
Data Availability
Raw reads of 16S rRNA gene sequencing data in this study were submitted and available in the Sequence Read Archive database of the National Center for Biotechnology Information (NCBI) in the bioproject PRJNA866344 with accession numbers from SAMN30161722 to SAMN30161765.
References
Aflatounian, A., Edwards, M. C., Rodriguez Paris, V., Bertoldo, M. J., Desai, R., Gilchrist, R. B., Ledger, W. L., Handelsman, D. J., & Walters, K. A. (2020). Androgen signaling pathways driving reproductive and metabolic phenotypes in a PCOS mouse model. Journal of Endocrinology, 245, 381–395.
Baumann, A., Nier, A., Hernández-Arriaga, A., Brandt, A., Lorenzo Pisarello, M. J., Jin, C. J., Pilar, E., Camarinha-Silva, A., Schattenberg, J. M., & Bergheim, I. (2021). Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease. Scientific Reports, 11, 17815.
Bokulich, N. A., Kaehler, B. D., Rideout, J. R., Dillon, M., Bolyen, E., Knight, R., Huttley, G. A., & Gregory Caporaso, J. (2018). Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2’s q2-feature-classifier plugin. Microbiome, 6, 90.
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2018). QIIME 2: Reproducible, interactive, scalable, and extensible microbiome data science. PeerJ Preprints, 6, e27295v2.
Brennan, C. A., & Garrett, W. S. (2016). Gut microbiota, inflammation, and colorectal cancer. Annual Review of Microbiology, 70, 395–411.
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J., & Holmes, S. P. (2015). DADA2: High resolution sample inference from amplicon data. bioRxiv. https://doi.org/10.1101/024034
Chang, Z. P., Deng, G. F., Shao, Y. Y., Xu, D., Zhao, Y. N., Sun, Y. F., Zhang, S. Q., Hou, R. G., & Liu, J. J. (2021). Shaoyao-Gancao Decoction ameliorates the inflammation state in polycystic ovary syndrome rats via remodeling gut microbiota and suppressing the TLR4/NF-κB pathway. Frontiers in Pharmacology, 12, 670054.
Clemente, J. C., Ursell, L. K., Parfrey, L. W., & Knight, R. (2012). The impact of the gut microbiota on human health: An integrative view. Cell, 148, 1258–1270.
Cuccherini, B., Chua, K., Gill, V., Weir, S., Wray, B., Stewart, D., Nelson, D., Fuss, I., & Strober, W. (2000). Bacteremia and skin/bone infections in two patients with X-linked agammaglobulinemia caused by an unusual organism related to Flexispira/Helicobacter species. Clinical Immunology, 97, 121–129.
Diamanti-Kandarakis, E., Papailiou, J., & Palimeri, S. (2006). Hyperandrogenemia: Pathophysiology and its role in ovulatory dysfunction in PCOS. Pediatric Endocrinology Reviews, 3, 198–204.
Franik, S., Kremer, J. A., Nelen, W. L., & Farquhar, C. (2014). Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews, 2, CD010287. https://doi.org/10.1002/14651858.cd010287.pub2
Gomes, A. C., Hoffmann, C., & Mota, J. F. (2018). The human gut microbiota: Metabolism and perspective in obesity. Gut Microbes, 9, 308–325.
Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011). Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. Nature Reviews Endocrinology, 7, 219–231.
Guo, Y., Qi, Y., Yang, X., Zhao, L., Wen, S., Liu, Y., & Tang, L. (2016). Association between polycystic ovary syndrome and gut microbiota. PLoS ONE, 11, e0153196.
Guo, J., Shao, J., Yang, Y., Niu, X., Liao, J., Zhao, Q., Wang, D., Li, S., & Hu, J. (2021). Gut microbiota in patients with polycystic ovary syndrome: A systematic review. Reproductive Sciences, 29, 69–83.
Hayes, M. G., Urbanek, M., Ehrmann, D. A., Armstrong, L. L., Lee, J. Y., Sisk, R., Karaderi, T., Barber, T. M., McCarthy, M. I., Franks, S., et al. (2015). Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nature Communications, 6, 7502.
He, Y., Wang, Q., Li, X., Wang, G., Zhao, J., Zhang, H., & Chen, W. (2020). Lactic acid bacteria alleviate polycystic ovarian syndrome by regulating sex hormone related gut microbiota. Food & Function, 11, 5192–5204.
Insenser, M., Murri, M., Del Campo, R., Martínez-García, M. Á., Fernández-Durán, E., & Escobar-Morreale, H. F. (2018). Gut microbiota and the polycystic ovary syndrome: Influence of sex, sex hormones, and obesity. Journal of Clinical Endocrinology and Metabolism, 103, 2552–2562.
Jobira, B., Frank, D. N., Pyle, L., Silveira, L. J., Kelsey, M. M., Garcia-Reyes, Y., Robertson, C. E., Ir, D., Nadeau, K. J., & Cree-Green, M. (2020). Obese adolescents with PCOS have altered biodiversity and relative abundance in gastrointestinal microbiota. Journal of Clinical Endocrinology and Metabolism, 105, e2134–e2144.
Jumpertz, R., Le, D. S., Turnbaugh, P. J., Trinidad, C., Bogardus, C., Gordon, J. I., & Krakoff, J. (2011). Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. The American Journal of Clinical Nutrition, 94, 58–65.
Kafali, H., Iriadam, M., Ozardali, I., & Demir, N. (2004). Letrozole-induced polycystic ovaries in the rat: A new model for cystic ovarian disease. Archives of Medical Research, 35, 103–108.
Kakoly, N. S., Khomami, M. B., Joham, A. E., Cooray, S. D., Misso, M. L., Norman, R. J., Harrison, C. L., Ranasinha, S., Teede, H. J., & Moran, L. J. (2018). Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: A systematic review and meta-regression. Human Reproduction Update, 24, 455–467.
La Marca, A., Egbe, T. O., Morgante, G., Paglia, T., Ciani, A., & De Leo, V. (2000). Metformin treatment reduces ovarian cytochrome P-450c17α response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Human Reproduction, 15, 21–23.
Lee, C. J., Sears, C. L., & Maruthur, N. (2020). Gut microbiome and its role in obesity and insulin resistance. Annals of the New York Academy of Sciences, 1461, 37–52.
Li, F., Jiang, C., Krausz, K. W., Li, Y., Albert, I., Hao, H., Fabre, K. M., Mitchell, J. B., Patterson, A. D., & Gonzalez, F. J. (2013). Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nature Communications, 4, 2384.
Li, X., Feng, Y., Lin, J. F., Billig, H., & Shao, R. (2014). Endometrial progesterone resistance and PCOS. Journal of Biomedical Science, 21, 2.
Li, N., Li, Y., Qian, C., Liu, Q., Cao, W., Ma, M., He, R., Chen, R., Geng, R., & Liu, Y. (2021). Dysbiosis of the saliva microbiome in patients with polycystic ovary syndrome. Frontiers in Cellular and Infection Microbiology, 10, 624504.
Lin, H., An, Y., Tang, H., & Wang, Y. (2019). Alterations of bile acids and gut microbiota in obesity induced by high fat diet in rat model. Journal of Agricultural and Food Chemistry, 67, 3624–3632.
Lin, W., Wen, L., Wen, J., & Xiang, G. (2021). Effects of sleeve gastrectomy on fecal gut microbiota and short-chain fatty acid content in a rat model of polycystic ovary syndrome. Frontiers in Endocrinology, 12, 747888.
Lindheim, L., Bashir, M., Münzker, J., Trummer, C., Zachhuber, V., Leber, B., Horvath, A., Pieber, T. R., Gorkiewicz, G., Stadlbauer, V., et al. (2017). Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): A pilot study. PLoS ONE, 12, e0168390.
Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016). Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertility and Sterility, 106, 6–15.
Naderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, H. J. (2015). Metformin and lifestyle modification in polycystic ovary syndrome: Systematic review and meta-analysis. Human Reproduction Update, 21, 560–574.
Palomba, S., de Wilde, M. A., Falbo, A., Koster, M. P., La Sala, G. B., & Fauser, B. C. (2015). Pregnancy complications in women with polycystic ovary syndrome. Human Reproduction Update, 21, 575–592.
Pichette, J., Fynn-Sackey, N., & Gagnon, J. (2017). Hydrogen sulfide and sulfate prebiotic stimulates the secretion of GLP-1 and improves glycemia in male mice. Endocrinology, 158, 3416–3425.
Piparva, K. G., & Buch, J. G. (2011). Deep vein thrombosis in a woman taking oral combined contraceptive pills. Journal of Pharmacology & Pharmacotherapeutics, 2, 185–186.
Qi, X., Yun, C., Sun, L., Xia, J., Wu, Q., Wang, Y., Wang, L., Zhang, Y., Liang, X., Wang, L., et al. (2019). Gut microbiota–bile acid–interleukin-22 axis orchestrates polycystic ovary syndrome. Nature Medicine, 25, 1225–1233.
Richards, J. S., Ren, Y. A., Candelaria, N., Adams, J. E., & Rajkovic, A. (2018). Ovarian follicular theca cell recruitment, differentiation, and impact on fertility: 2017 update. Endocrine Reviews, 39, 1–20.
Rosenfield, R. L., & Ehrmann, D. A. (2016). The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine Reviews, 37, 467–520.
Sasaki, H., Kawamura, K., Kawamura, T., Odamaki, T., Katsumata, N., Xiao, J. Z., Suzuki, N., & Tanaka, M. (2019). Distinctive subpopulations of the intestinal microbiota are present in women with unexplained chronic anovulation. Reproductive Biomedicine Online, 38, 570–578.
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011). Metagenomic biomarker discovery and explanation. Genome Biology, 12, R60.
Shao, J., Liu, Y., Wang, H., Luo, Y., & Chen, L. (2020). An integrated fecal microbiome and metabolomics in T2DM rats reveal antidiabetes effects from host-microbial metabolic axis of EtOAc extract from Sophora flavescens. Oxidative Medicine and Cellular Longevity, 2020, 1805418.
Shen, L. Y., Chang, X. F., Pan, L., Liu, X. J., Yang, Z. F., & Hu, H. (2021). Effect of electroacupuncture on expression of Kisspeptin protein in hypothalamus of rats with polycystic ovary syndrome. Acupuncture Research, 46, 106–110. https://doi.org/10.13702/j.1000-0607.200497
Snider, A. P., & Wood, J. R. (2019). Obesity induces ovarian inflammation and reduces oocyte quality. Reproduction, 158, R79–R90.
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., Andersen, M., Azziz, R., et al. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertility and Sterility, 110, 364–379.
Torres, P. J., Skarra, D. V., Ho, B. S., Sau, L., Anvar, A. R., Kelley, S. T., & Thackray, V. G. (2019). Letrozole treatment of adult female mice results in a similar reproductive phenotype but distinct changes in metabolism and the gut microbiome compared to pubertal mice. BMC Microbiology, 19, 57.
Toscano, M., De Grandi, R., Stronati, L., De Vecchi, E., & Drago, L. (2017). Effect of Lactobacillus rhamnosus HN001 and Bifidobacterium longum BB536 on the healthy gut microbiota composition at phyla and species level: A preliminary study. World Journal of Gastroenterology, 23, 2696–2704.
Tremellen, K., & Pearce, K. (2012). Dysbiosis of gut microbiota (DOGMA)–a novel theory for the development of polycystic ovarian syndrome. Medical Hypotheses, 79, 104–112.
Tzotzas, T., Karras, S. N., & Katsiki, N. (2017). Glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of obese women with polycystic ovary syndrome. Current Vascular Pharmacology, 15, 218–229.
Wang, H., Wang, X., Zhu, Y., Chen, F., Sun, Y., & Han, X. (2015). Increased androgen levels in rats impair glucose-stimulated insulin secretion through disruption of pancreatic beta cell mitochondrial function. The Journal of Steroid Biochemistry and Molecular Biology, 154, 254–266.
Wang, J., Wu, D., Guo, H., & Li, M. (2019). Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome. Life Sciences, 236, 116940.
Wang, Z., Zhu, H., Jiang, Q., & Zhu, Y. Z. (2021). The gut microbiome as non-invasive biomarkers for identifying overweight people at risk for osteoarthritis. Microbial Pathogenesis, 157, 104976.
Wolf, W. M., Wattick, R. A., Kinkade, O. N., & Olfert, M. D. (2018). Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. International Journal of Environmental Research and Public Health, 15, 2589.
Wu, Q., Gao, J., Bai, D., Yang, Z., & Liao, Q. (2021). The prevalence of polycystic ovarian syndrome in Chinese women: A meta-analysis. Annals of Palliative Medicine, 10, 74–87.
Yang, T., Santisteban, M. M., Rodriguez, V., Li, E., Ahmari, N., Carvajal, J. M., Zadeh, M., Gong, M., Qi, Y., Zubcevic, J., Sahay, B., et al. (2015). Gut dysbiosis is linked to hypertension. Hypertension, 65, 1331–1340.
Yang, Y. L., Zhou, W. W., Wu, S., Tang, W. L., Wang, Z. W., Zhou, Z. Y., Li, Z. W., Huang, Q. F., He, Y., & Zhou, H. W. (2021). Intestinal flora is a key factor in insulin resistance and contributes to the development of polycystic ovary syndrome. Endocrinology, 162, bqab118.
Yu, Y., Cao, Y., Huang, W., Liu, Y., Lu, Y., & Zhao, J. (2021). β-Sitosterol ameliorates endometrium receptivity in PCOS-like mice: The mediation of gut microbiota. Frontiers in Nutrition, 8, 667130.
Zhao, X., Jiang, Y., Xi, H., Chen, L., & Feng, X. (2020). Exploration of the relationship between gut microbiota and polycystic ovary syndrome (PCOS): A review. Geburtshilfe Und Frauenheilkunde, 80, 161–171.
Zhou, L., Ni, Z., Cheng, W., Yu, J., Sun, S., Zhai, D., Yu, C., & Cai, Z. (2020). Characteristic gut microbiota and predicted metabolic functions in women with PCOS. Endocrine Connections, 9, 63–73.
Acknowledgements
This work was supported by the Advantages Discipline Group (Biology and Medicine) Project in Higher Education of Hubei Province (2021–2025) (2022BMXKQY4), Cultivating Project for Young Scholar at Hubei University of Medicine (2016QDJZR17), National Undergraduate Training Program for Innovation and Entrepreneurship (S202210929003, S202210929005, S202110929010, 202013249003), the Scientific and Technological Project of Shiyan City of Hubei Province (No. 22Y26), and Scientific research Project of Hubei Provincial Health Commission (WJ2023M169).
Author information
Authors and Affiliations
Contributions
WJJ, ZJ, QXM and FL conceptualized and designed the research; WJJ, ZJ, QXM, MSH, CXJ, CZY and WRZ conducted the research; WJJ, ZJ, JYF, TY and FL interpreted and analyzed the results; WJJ and ZJ wrote the original draft of the paper; WJJ and QXM acquired funding.
Corresponding authors
Ethics declarations
Conflict of Interest
The authors declare that there are no conflicts of interest.
Ethical Approval
The study for clinical samples and animal study was reviewed and approved by the Human Ethics Committee and the Experimental Animal Ethics Committee of the Hubei University of Medicine under permit numbers HBMU2020-S-H072 and HBMU2021-S109.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zhou, J., Qiu, X., Chen, X. et al. Comprehensive Analysis of Gut Microbiota Alteration in the Patients and Animal Models with Polycystic Ovary Syndrome. J Microbiol. 61, 821–836 (2023). https://doi.org/10.1007/s12275-023-00079-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12275-023-00079-9